GO:0004155 6,7-dihydropteridine reductase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004155 describes the enzymatic activity that reduces 6,7-dihydropteridine back to 5,6,7,8-tetrahydropteridine using NAD(P)H as the electron donor.
• This activity is essential for recycling tetrahydrobiopterin (BH4), the obligatory cofactor for phenylalanine hydroxylase, tyrosine hydroxylase, and tryptophan hydroxylase.
• In humans, the enzyme is encoded by QDPR (quinoid dihydropteridine reductase); biallelic QDPR mutations cause dihydropteridine reductase deficiency, a rare inherited hyperphenylalaninemia with severe neurological consequences.
• Dihydropteridine reductase (DHPR) also exhibits NADH-ferric reductase activity and, in Escherichia coli, dihydrofolate reductase activity, indicating broader redox roles beyond pterin recycling.
• DHPR is a validated target for studying BH4 metabolism, neurotransmitter biosynthesis, and cerebral folate deficiency.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable precise dissection of QDPR function in cell and animal systems.
Description
6,7-dihydropteridine reductase activity (GO:0004155) is a molecular function that catalyzes the NAD(P)H-dependent reduction of 6,7-dihydropteridine to 5,6,7,8-tetrahydropteridine, the active cofactor form of tetrahydrobiopterin (BH4). This reaction is the final step in the BH4 regeneration pathway, ensuring a continuous supply of reduced pterin for aromatic amino acid hydroxylases. Because BH4 is required for phenylalanine, tyrosine, and tryptophan hydroxylation, loss of this activity disrupts neurotransmitter synthesis and phenylalanine homeostasis. The enzyme responsible, dihydropteridine reductase (DHPR), is encoded by QDPR in humans and has been studied for decades in the context of inherited hyperphenylalaninemia and neurological disease. Beyond its canonical role, DHPR has been reported to possess NADH-ferric reductase activity and, in Escherichia coli, dihydrofolate reductase activity, suggesting additional redox functions. Researchers investigating pterin metabolism, oxidative stress, and neurochemistry therefore rely on accurate models of GO:0004155 to link genotype to biochemical and clinical phenotypes.
6,7-dihydropteridine reductase activity At A Glance
| GO ID | GO:0004155 |
|---|---|
| GO term | 6,7-dihydropteridine reductase activity |
| Ontology | molecular_function |
| Synonym | DHPR activity; dihydropteridine reductase activity; NAD(P)H2:6,7-dihydropteridine oxidoreductase activity |
| Major function | Regeneration of 5,6,7,8-tetrahydropteridine (BH4) from 6,7-dihydropteridine using NAD(P)H |
| Reaction | NAD(P)+ + 5,6,7,8-tetrahydropteridine = NAD(P)H + H+ + 6,7-dihydropteridine |
| Human gene | QDPR (quinoid dihydropteridine reductase) |
| Associated disease | Dihydropteridine reductase deficiency; hyperphenylalaninemia |
| Cofactor | NADH or NADPH |
What Is GO:0004155?
GO:0004155, 6,7-dihydropteridine reductase activity, is defined as the catalysis of the reaction NAD(P)+ + 5,6,7,8-tetrahydropteridine = NAD(P)H + H+ + 6,7-dihydropteridine. In other words, the enzyme transfers electrons from NAD(P)H to 6,7-dihydropteridine, regenerating the fully reduced tetrahydropteridine cofactor.
Why Is 6,7-dihydropteridine reductase activity Important in Cell Biology?
GO:0004155 is central to tetrahydrobiopterin (BH4) homeostasis, which is required for the hydroxylation of phenylalanine, tyrosine, and tryptophan. Defects in this activity cause dihydropteridine reductase deficiency, a rare but treatable cause of hyperphenylalaninemia that, if unrecognized, leads to severe neurological impairment. Because BH4 also supports nitric oxide synthase and other enzymes, altered DHPR activity can influence vascular and neuronal signaling. Studying this activity therefore bridges enzymology, metabolic disease, and neurochemistry.
• Maintains the pool of reduced BH4 needed for phenylalanine hydroxylase, preventing hyperphenylalaninemia.
• Supports tyrosine and tryptophan hydroxylation, and thus dopamine and serotonin biosynthesis.
• Its deficiency is a differential diagnosis in newborns with hyperphenylalaninemia who do not respond to a phenylalanine-restricted diet.
• DHPR has additional NADH-ferric reductase activity, linking pterin metabolism to iron/redox biology.
• In E. coli, DHPR exhibits dihydrofolate reductase activity, connecting pterin and folate pathways.
• Altered BH4 metabolism has been associated with cerebral folate deficiency and neurological dysfunction.
• Provides a biochemical marker for monitoring cofactor therapy in inherited hyperphenylalaninemias.
• Serves as a model enzyme for studying NAD(P)H-dependent oxidoreductase mechanisms.
• Enables structure-function studies using stable quinonoid dihydropterin substrates.
• Supports comparative enzymology with dihydrofolate reductase using 7,8-dihydropteridines.
What Happens During 6,7-dihydropteridine reductase activity?
Substrate binding and cofactor selection
In simple terms: The enzyme grabs the used-up pterin and a helper molecule called NADH or NADPH.
DHPR binds 6,7-dihydropteridine, the oxidized pterin that results from hydroxylase reactions, together with either NADH or NADPH as the electron donor. The enzyme can use both reduced nicotinamide cofactors, although NADH is often considered the preferred substrate in mammalian systems. Stable quinonoid dihydropterin analogs, such as 6,6-dimethylpterins, have been used to study substrate recognition and catalysis.
Hydride transfer and pterin reduction
In simple terms: The helper molecule hands over a tiny particle to turn the used pterin back into its active form.
The catalytic step involves hydride transfer from NAD(P)H to 6,7-dihydropteridine, yielding NAD(P)+ and 5,6,7,8-tetrahydropteridine. This reduction regenerates the tetrahydro form of the cofactor, which is the oxidation state required by aromatic amino acid hydroxylases. The reaction is essential because non-enzymatic reduction of quinonoid dihydropterin is too slow to sustain hydroxylase activity.
Cofactor recycling and metabolic coupling
In simple terms: The regenerated pterin is immediately reused by other enzymes that need it.
Once 5,6,7,8-tetrahydropteridine is regenerated, it can be used again by phenylalanine hydroxylase, tyrosine hydroxylase, and tryptophan hydroxylase. This recycling loop couples DHPR activity to phenylalanine catabolism and neurotransmitter biosynthesis. Inborn errors in this loop, including QDPR deficiency, lead to hyperphenylalaninemia and neurotransmitter depletion.
Alternative redox activities
In simple terms: The same enzyme can also help with iron and folate chemistry in some organisms.
Beyond pterin reduction, DHPR has been reported to exhibit NADH-ferric reductase activity, suggesting a role in iron redox metabolism. In Escherichia coli, dihydropteridine reductase also displays dihydrofolate reductase activity, indicating overlap with folate pathways. Comparative studies with rat liver dihydrofolate reductase using 7,8-dihydrofolate and other 7,8-dihydropteridines further illustrate the broader pteridine substrate range of these enzymes.
Key Genes Involved in GO:0004155 6,7-dihydropteridine reductase activity
The following genes and proteins are directly or functionally linked to 6,7-dihydropteridine reductase activity and its metabolic context.
| Gene | Major Role | Research Relevance |
|---|---|---|
| QDPR | Encodes human dihydropteridine reductase (DHPR) | Primary gene for GO:0004155; mutations cause DHPR deficiency |
| PAH | Phenylalanine hydroxylase; uses BH4 to convert phenylalanine to tyrosine | Loss causes phenylketonuria; BH4 recycling by DHPR is essential |
| TH | Tyrosine hydroxylase; uses BH4 for dopamine synthesis | DHPR supports neurotransmitter synthesis |
| TPH1 | Tryptophan hydroxylase 1; uses BH4 for serotonin synthesis | Peripheral serotonin production depends on BH4 regeneration |
| TPH2 | Tryptophan hydroxylase 2; neuronal serotonin synthesis | Central serotonin synthesis relies on BH4 |
| GCH1 | GTP cyclohydrolase 1; rate-limiting BH4 biosynthesis | Defects cause BH4-deficient hyperphenylalaninemia |
| PTS | 6-pyruvoyltetrahydropterin synthase; BH4 biosynthesis | Mutations cause BH4 deficiency |
| SPR | Sepiapterin reductase; BH4 biosynthesis | Defects cause BH4 deficiency and neurological disease |
| DHFR | Dihydrofolate reductase; folate metabolism | Shares pteridine substrates with DHPR; E. coli DHPR shows DHFR activity |
| MTHFR | Methylenetetrahydrofolate reductase; folate cycle | Linked to cerebral folate deficiency and BH4-related disorders |
| FOLR1 | Folate receptor alpha; folate transport | Cerebral folate deficiency can co-occur with BH4 disorders |
| NOS1 | Neuronal nitric oxide synthase; uses BH4 | BH4 availability affects nitric oxide signaling |
| NOS2 | Inducible nitric oxide synthase; uses BH4 | BH4 recycling influences inflammatory NO production |
| NOS3 | Endothelial nitric oxide synthase; uses BH4 | DHPR activity may affect vascular BH4 pools |
| PCBD1 | Pterin-4 alpha-carbinolamine dehydratase; BH4 regeneration | Works upstream of DHPR in BH4 recycling |
| QDPR (E. coli homolog) | Bacterial dihydropteridine reductase | Model for studying dual DHPR/DHFR activity |
| GCH1 (GTP cyclohydrolase) | BH4 biosynthesis | Regulates BH4 supply for DHPR-dependent recycling |
How Is 6,7-dihydropteridine reductase activity Regulated?
The activity of 6,7-dihydropteridine reductase is primarily regulated by substrate availability (6,7-dihydropteridine generated by hydroxylase reactions) and the cellular redox state of NADH/NADPH. BH4 biosynthesis enzymes such as GCH1, PTS, and SPR determine the total pterin pool, indirectly influencing DHPR flux. Inborn errors in QDPR reduce enzyme activity and cause hyperphenylalaninemia, illustrating that genetic regulation of QDPR expression is critical for metabolic homeostasis. Additionally, because DHPR can use both NADH and NADPH, shifts in nicotinamide cofactor balance may modulate its activity. No specific allosteric regulator of DHPR has been firmly established in the cited literature, so regulation is best described in terms of substrate supply, cofactor availability, and gene expression.
6,7-dihydropteridine reductase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| QDPR | Dihydropteridine reductase deficiency; hyperphenylalaninemia | QDPR knockout cell line; patient-derived fibroblasts |
| PAH | Phenylketonuria; hyperphenylalaninemia | PAH mutant knock-in models; BH4 cofactor studies |
| GCH1 | BH4-deficient hyperphenylalaninemia; dopa-responsive dystonia | GCH1 knockout or point-mutation models |
| PTS | BH4 deficiency with neurological symptoms | PTS knockout cell and animal models |
| FOLR1 | Cerebral folate deficiency | FOLR1 knockout or knockdown models |
Dihydropteridine reductase deficiency and hyperphenylalaninemia
Biallelic mutations in QDPR cause dihydropteridine reductase deficiency, an inherited disorder of BH4 metabolism characterized by hyperphenylalaninemia and neurological symptoms. Unlike classical phenylketonuria, DHPR deficiency is not fully corrected by a phenylalanine-restricted diet because neurotransmitter synthesis is also impaired. Early diagnosis and cofactor therapy are essential to prevent irreversible neurological damage.
Cerebral folate deficiency and neurological dysfunction
Disorders of biopterin metabolism, including DHPR deficiency, can be associated with cerebral folate deficiency, a condition marked by low cerebrospinal fluid folate despite normal serum folate. This association highlights the interplay between pterin recycling and folate transport in the brain. Patients may present with developmental delay, seizures, and movement disorders.
Redox and iron metabolism connections
DHPR has been reported to possess NADH-ferric reductase activity, suggesting a potential role in iron redox homeostasis beyond pterin recycling. This finding expands the biological relevance of GO:0004155 to oxidative stress and metal metabolism. However, the physiological significance of this activity in human disease remains an active area of research.
From 6,7-dihydropteridine reductase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of QDPR impair BH4 regeneration? | QDPR knockout cell line |
| Can a specific QDPR missense mutation cause DHPR deficiency? | Point-mutation knock-in of the patient variant |
| Does restoring QDPR expression rescue hyperphenylalaninemia? | Knock-in or overexpression of wild-type QDPR |
| Where is DHPR localized in the cell? | Tagged knock-in with fluorescent or epitope tag |
| Does DHPR have ferric reductase activity in vivo? | Overexpression and biochemical assays |
| Can DHPR compensate for DHFR loss in bacteria? | E. coli knockout and complementation models |
How to Study the 6,7-dihydropteridine reductase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| DHPR activity assay | NADH/NADPH oxidation coupled to pterin reduction | Diagnosis of DHPR deficiency |
| HPLC/LC-MS/MS | BH4 and pterin metabolite levels | Metabolic profiling in cells and fluids |
| Sanger sequencing | QDPR mutations | Genetic diagnosis of hyperphenylalaninemia |
| CRISPR knockout | Loss of QDPR function | Functional studies in cell lines |
| Western blot | DHPR protein expression | Validation of knockout or overexpression |
| Fluorescence microscopy | Subcellular localization of tagged DHPR | Localization studies |
| RNA-seq | Transcriptome changes after QDPR perturbation | Pathway analysis |
| NADH-ferric reductase assay | Iron reduction capacity | Redox function studies |
Enzymatic activity assays
DHPR activity is typically measured spectrophotometrically by monitoring the NADH or NADPH oxidation that accompanies reduction of 6,7-dihydropteridine. Stable quinonoid dihydropterin substrates, such as 6,6-dimethylpterins, facilitate reproducible kinetic measurements. These assays are used to confirm loss-of-function in patient samples and CRISPR models.
Genetic and genomic analysis
Sanger sequencing and next-generation sequencing of QDPR are used to identify pathogenic variants in patients with hyperphenylalaninemia. CRISPR knockout and knock-in models can be validated by targeted sequencing and off-target analysis. Gene expression can be quantified by RT-qPCR or RNA-seq.
Metabolite profiling
BH4 and its oxidized pterin derivatives can be quantified by HPLC or LC-MS/MS in cells and body fluids. Phenylalanine and tyrosine levels are measured to assess hydroxylase function. Cerebrospinal fluid folate and neurotransmitter metabolites are used to evaluate cerebral folate deficiency.
Protein and localization studies
Western blotting and immunoprecipitation can detect DHPR protein levels and interactions. Fluorescent tagging or epitope tagging enables subcellular localization studies. These methods complement activity assays to distinguish expression defects from catalytic defects.
How CRISPR Can Be Used to Study GO:0004155 6,7-dihydropteridine reductase activity
Knockout
CRISPR knockout of QDPR can create isogenic cell lines lacking DHPR activity, enabling studies of BH4 regeneration, phenylalanine metabolism, and neurotransmitter synthesis. These models are useful for validating patient variants and testing rescue strategies.
Point Mutation
Point-mutation knock-in of specific QDPR variants identified in patients allows precise genotype-phenotype correlation. Such models can reveal whether a missense change affects catalytic activity, protein stability, or cofactor binding.
Knock-in
Knock-in of wild-type or tagged QDPR can restore function in knockout backgrounds or enable localization and interaction studies. Tagged knock-in lines are valuable for proteomic and imaging experiments.
Overexpression
Overexpression of QDPR can be used to study gain-of-function effects, including potential ferric reductase activity and effects on BH4 pools. Overexpression models also help test whether increased DHPR activity can compensate for other metabolic defects.
How EDITGENE Supports 6,7-dihydropteridine reductase activity Research
Researchers studying 6,7-dihydropteridine reductase activity-related genes often need to determine whether a candidate gene is causally involved in BH4 metabolism, hyperphenylalaninemia, or neurotransmitter dysfunction. EDITGENE provides CRISPR-based cell models and screening services to accelerate this causal validation.
Contact EDITGENE today to design your custom CRISPR model for 6,7-dihydropteridine reductase activity research.
Frequently Asked Questions About 6,7-dihydropteridine reductase activity
What is 6,7-dihydropteridine reductase activity?
It is the enzymatic activity (GO:0004155) that reduces 6,7-dihydropteridine to 5,6,7,8-tetrahydropteridine using NADH or NADPH, regenerating the BH4 cofactor.
What gene encodes 6,7-dihydropteridine reductase in humans?
The human gene is QDPR, which encodes quinoid dihydropteridine reductase.
What diseases are associated with 6,7-dihydropteridine reductase deficiency?
Biallelic QDPR mutations cause dihydropteridine reductase deficiency, a form of hyperphenylalaninemia with neurological symptoms.
What reaction does GO:0004155 catalyze?
It catalyzes NAD(P)+ + 5,6,7,8-tetrahydropteridine = NAD(P)H + H+ + 6,7-dihydropteridine.
Why is 6,7-dihydropteridine reductase important for neurotransmitter synthesis?
It regenerates BH4, which is required by tyrosine and tryptophan hydroxylases for dopamine and serotonin production.
Does dihydropteridine reductase have other enzymatic activities?
Yes, it has been reported to exhibit NADH-ferric reductase activity and, in E. coli, dihydrofolate reductase activity.
How is 6,7-dihydropteridine reductase activity measured?
It is typically measured by spectrophotometric assays monitoring NADH or NADPH oxidation in the presence of 6,7-dihydropteridine.
What is the relationship between DHPR and cerebral folate deficiency?
Disorders of biopterin metabolism, including DHPR deficiency, can be associated with cerebral folate deficiency.
Can CRISPR be used to study QDPR function?
Yes, CRISPR knockout, point-mutation, knock-in, and overexpression models enable precise functional studies of QDPR.
What model systems are used to study 6,7-dihydropteridine reductase activity?
Cell lines, patient-derived fibroblasts, and animal models with QDPR or other BH4 pathway gene perturbations are commonly used.
Conclusion
6,7-dihydropteridine reductase activity (GO:0004155) is a critical enzymatic function for regenerating tetrahydrobiopterin and sustaining aromatic amino acid hydroxylation. Its deficiency causes a rare but severe form of hyperphenylalaninemia with neurological consequences, making it an important target for metabolic and neurochemical research. CRISPR-based models provide powerful tools to dissect QDPR function and to test therapeutic strategies for BH4-related disorders.
References
- 1. Adam MP et al.. 1993. Dihydropteridine Reductase Deficiency.. PMID: 42228786
- 2. Lee PL et al.. 2000. NADH-ferric reductase activity associated with dihydropteridine reductase.. Biochem Biophys Res Commun 271(3):788-95 PMID: 10814540
- 3. Vasudevan SG et al.. 1992. Dihydropteridine reductase from Escherichia coli exhibits dihydrofolate reductase activity.. Biol Chem Hoppe Seyler 373(10):1067-73 PMID: 1418677
- 4. Longo N. 2009. Disorders of biopterin metabolism.. J Inherit Metab Dis 32(3):333-42 PMID: 19234759
- 5. Ramaekers VT et al.. 2004. Cerebral folate deficiency.. Dev Med Child Neurol 46(12):843-51 PMID: 15581159
- 6. Blau N. 2016. Genetics of Phenylketonuria: Then and Now.. Hum Mutat 37(6):508-15 PMID: 26919687
- 7. Bailey SW et al.. 1983. 6,6-Dimethylpterins: stable quinoid dihydropterin substrate for dihydropteridine reductase and tetrahydropterin cofactor for phenylalanine hydroxylase.. Biochemistry 22(8):1790-8 PMID: 6849887
- 8. Webber S et al.. 1985. Comparative activity of rat liver dihydrofolate reductase with 7,8-dihydrofolate and other 7,8-dihydropteridines.. Arch Biochem Biophys 236(2):681-90 PMID: 3970530
